Zoladex SC Injection 3.6 mg

Zoladex SC Injection 3.6 mg Uses, Dosage, Side Effects, Food Interaction and all others data.

Zoladex SC Injection 3.6 mg is a synthetic hormone. In men, it stops the production of the hormone testosterone, which may stimulate the growth of cancer cells. In women, goserelin decreases the production of the hormone estradiol (which may stimulate the growth of cancer cells) to levels similar to a postmenopausal state. When the medication is stopped, hormone levels return to normal.

The pharmacokinetics of goserelin have been determined in both male and female healthy volunteers and patients. In these studies, goserelin was administered as a single 250µg (aqueous solution) dose and as a single or multiple 3.6 mg depot dose by subcutaneous route.

Zoladex SC Injection 3.6 mg
Uses
Dosage
Side Effect
Precautions
Interactions
Uses during Pregnancy
Uses during Breastfeeding
Accute Overdose
Food Interaction
Half Life
Volume of Distribution
Clearance
Interaction With other Medicine
Contradiction
Storage

Trade Name	Zoladex SC Injection 3.6 mg
Availability	Prescription only
Generic	Goserelin
Goserelin Other Names	Goserelin, Goserelina
Related Drugs	estradiol, tamoxifen, Premarin, testosterone, tranexamic acid, norethindrone, medroxyprogesterone, megestrol, Xtandi, Provera
Weight	3.6 mg
Type	SC Injection
Formula	C₅₉H₈₄N₁₈O₁₄
Weight	Average: 1269.4105 Monoisotopic: 1268.641439486
Protein binding	27.3%
Groups	Approved
Therapeutic Class
Manufacturer	MGH Healthcare Limited
Available Country	Bangladesh
Last Updated:	October 19, 2023 at 6:27 am

Uses

Zoladex SC Injection 3.6 mg is a synthetic analog of luteinizing hormone-releasing hormone used to treat breast cancer and prostate cancer by reducing secretion of gonadotropins from the pituitary.

Zoladex SC Injection 3.6 mg is indicated for:

Use in combination with flutamide for the management of locally confined carcinoma of the prostate
Palliative treatment of advanced carcinoma of the prostate
The management of endometriosis
Use as an endometrial-thinning agent prior to endometrial ablation for dysfunctional uterine bleeding
Use in the palliative treatment of advanced breast cancer in pre- and perimenopausal women

Zoladex SC Injection 3.6 mg is also used to associated treatment for these conditions: Advanced Breast Cancer, Early Breast Cancer, Endometriosis, Advanced carcinoma of the prostate, Stage M1 hormone dependent carcinoma of the prostate, Stage T2b carcinoma of the prostate, Stage T2c carcinoma of the prostate, Stage T3 carcinoma of the prostate, Stage T4 carcinoma of the prostate, Endometrial thinning prior to endometrial ablation for dysfunctional uterine bleeding

How Zoladex SC Injection 3.6 mg works

Zoladex SC Injection 3.6 mg is a synthetic decapeptide analogue of LHRH. Zoladex SC Injection 3.6 mg acts as a potent inhibitor of pituitary gonadotropin secretion when administered in the biodegradable formulation. The result is sustained suppression of LH and serum testosterone levels.

Toxicity

No experience of overdosage from clinical trials.

Food Interaction

No interactions found.

Zoladex SC Injection 3.6 mg Drug Interaction

Moderate: glycerin, glycerinMinor: sulfamethoxazole / trimethoprim, sulfamethoxazole / trimethoprimUnknown: aspirin, aspirin, calcium / vitamin d, calcium / vitamin d, ubiquinone, ubiquinone, copper gluconate, copper gluconate, acetaminophen, acetaminophen, bioflavonoids, bioflavonoids, valproic acid, valproic acid, cholecalciferol, cholecalciferol

Zoladex SC Injection 3.6 mg Disease Interaction

Moderate: bone mineral density, CV disease, hyperglycemia, QTc interval prolongation

Volume of Distribution

44.1 ± 13.6 L [subcutaneous administration of 250 mcg]

Elimination Route

Inactive orally, rapidly absorbed following subcutaneous administration.

Half Life

4-5 hours

Clearance

121 +/- 42.4 mL/min [prostate cancer with 10.8 mg depot]

Elimination Route

Clearance of goserelin following subcutaneous administration of a radiolabeled solution of goserelin was very rapid and occurred via a combination of hepatic and urinary excretion. More than 90% of a subcutaneous radiolabeled solution formulation dose of goserelin was excreted in urine.